Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
Type 1 Issues Archives
Print | Email | Share | Comments (5)

Small Bedtime Dose of Terbutaline May Prevent Type 1 Hypoglycemia

Dec 29, 2008

Terbutaline, which goes under the trade names Brethine, Bricanyl, and Brethaire, is typically used as a fast-acting bronchodilator in asthma patients. Doctors also use it to delay premature labor. More research is needed to see if it can help type 1s.

A study of the effectiveness of the drug terbutaline on controlling nighttime hypoglycemia in people with type 1 diabetes indicates that it may be a safe and useful treatment with no ill effects.

Researchers at the Washington University School of Medicine in St. Louis studied 15 type 1 patients (average A1c: 7.1%) to see if terbutaline could prevent hypoglycemic episodes during sleep without causing hyperglycemia the following morning. 

(Terbutaline, which goes under the trade names Brethine, Bricanyl, and Brethaire, is typically used as a fast-acting bronchodilator in asthma patients. Doctors also use it to delay premature labor.)

Some patients were randomly assigned a dose of 2.5 mg of terbutaline each night before going to sleep. A second group received a 5 mg dose. A third group received a placebo. The patients received their respective doses at 10 p.m. on three separate nights.

The mean lowest plasma glucose concentrations at night among the groups were:

  • 2.5 mg: 100 mg/dl
  • 5 mg: 122 mg/dl
  • Placebo: 87 mg/dl

Morning plasma glucose levels were:

  • 2.5 mg: 127 mg/dl
  • 5 mg: 183 mg/dl
  • Placebo: 113 mg/dl

Although the mean figures for the 2.5 mg terbutaline group seem to be closer to the ideal, seven patients in the group reached a nadir nocturnal concentration of 70 mg/dl; six reached 60 mg/dl; and two reached 50 mg/dl in the course of the study. While three patients in the 5 mg group reached a nadir of 70 mg/dl, none in the group reached a lower level. 

The researchers had previously reported on the effectiveness of a 5 mg dose of terbutaline, but were concerned that its morning plasma glucose levels were high. While the study tentatively established the effectiveness of the 2.5 mg dose, researchers have called for a much longer, more extensive trial of the drug among type 1s.


Categories: A1c Test, Diabetes, Diabetes, Low Blood Sugar, Medications, Medications Research, Type 1 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Dec 29, 2008

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.